Disclosed herein are methods and systems for clinical practice of medical imaging on patients with metal-containing devices, such as implanted cardiac devices. In particular, Disclosed herein are methods and systems for improved late gadolinium enhancement (LGE) MRI for assessing myocardial viability for patients with implanted cardiac devices, i.e., cardiac pacemakers and implantable cardiac defibrillators.

The present disclosure relates to the generation of artificial MRI images of the liver. The disclosure also relates to a method, a system and a computer program product for generating MRI images of the liver without contract enhancement.

Methods of ex vivo labeling of a biological material for in vivo imaging, methods of labeling a biological material in vivo, methods for preparing a labeling agent, and methods for in vivo imaging of a subject using a biological material labeled with a labeling agent are disclosed. In one non-limiting example, the biological material is selected from cells and the labeling agent is a .sup.89Zr-Desferrioxamine-NCS labeling agent.

The present invention relates to pharmaceutical compositions comprising an gadolinium-complex and a saturated macrocyclic tetraamine that find application in diagnostic imaging as diagnostic agents, in particular as contrast agents having improved tolerability, specifically in Magnetic Resonance Imaging (MRI), and to their preparation.

Disclosed herein is a method for multimodal imaging during a medical procedure using magnetic resonance imaging (MRI) and Raman optical imaging which involves administering an MRI imaging contrast agent that a chemical structure having charge-transfer electronic transitions. The tissue is imaged using and MRI device and the tissue is illuminated with excitation light that has spectral components that are approximately tuned close to one of the charge-transfer electronic transitions thereby producing enhanced Raman optical signals which are analyzed to produce Raman imaging data followed by registering the MRI and Raman imaging data. The present disclosure also provides a method for ionizing laser plumes through atmospheric pressure chemical ionization.

A magnetic resonance imaging (MRI) contrast agent and a preparation method and a use thereof is provided, which belong to the technical field of Magnetic Resonance Imaging contrast agent. The MRI contrast agent is prepared by the compound having a structure of formula I; and it also may include the compound having a structure of formula II or a pharmaceutically acceptable salt thereof, wherein M.sub.1 is a divalent ion or a trivalent ion of a paramagnetic metal selected from Mn, Fe, Eu, or Dy; M.sub.2 is selected from Na.sup.+, K.sup.+ or meglumine cation; when M.sub.1 is a divalent ion, a is 2; when M.sub.1 is a trivalent ion, a is 3. The MRI contrast agent has good water solubility, high relaxivity, and low toxic and side effect.

##STR00001##

The present disclosure deals with the quickening of MRI examinations. Subjects of the present disclosure are a method, a system, a computer program product, a use, a contrast agent for use and a kit.

The present invention relates to an iron complex having the general formula (I) or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition formulated for oral and/or parenteral administration, preferably intravenous, said pharmaceutical composition preferably being formulated as an aqueous solution comprising said complex or salt. The present invention further relates to said complex or a salt thereof or said pharmaceutical composition for use as a contrast agent for magnetic resonance imaging (MRI), as well as a method and a kit for in situ preparation of said complex or salt and said pharmaceutical composition.

The invention provides novel iron(III) complexes with formulae (1) and (2). Furthermore, corresponding ligands with formulae (L1) and (L2) for the production of iron(III) complexes are disclosed.

##STR00001##

[Problem] To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc. [Solution] When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.